Foreign Filer Report • Aug 19, 2025
Preview not available for this file type.
Download Source File6-K 1 f6k_081925.htm FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____
FORM 6-K
____
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 19, 2025
____
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
____
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☒ Form 40-F ☐
Field: Page; Sequence: 1
Field: /Page
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 19 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
Field: Page; Sequence: 2
Field: /Page
Page 2 of 3
| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name of the Board member/Executive/Associated Person | Christina Law | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | Member of the Board of Directors | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description of the financial instrument, type of instrument, | ADRs | |
| | Identification code | NVO | |
| b) | Nature of the transaction | Purchase of ADRs | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | DKK 349.06 | 952 ADRs |
| | | DKK 349.04 | 598 ADRs |
| | | DKK 349.03 | 800 ADRs |
| d) | Aggregated information · Aggregated volume · Price | 2,350 ADRs DKK 820,252.49 | |
| e) | Date of the transaction | 2025-08- 18 | |
| f) | Place of the transaction | New York Stock Exchange | |
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Field: Page; Sequence: 3
Field: /Page
Page 3 of 3
Contacts for further information
| Media: | |
|---|---|
| Ambre James- Brown +45 3079 9289 [email protected] | Liz Skrbkova (US) +1 609 917 0632 [email protected] |
| Investors: | |
| Jacob Martin Wiborg Rode +45 3075 5956 [email protected] | Sina Meyer +45 3079 6656 [email protected] |
| Max Ung +45 3077 6414 [email protected] | Christoffer Sho Togo Tullin +45 3079 1471 [email protected] |
| Alex Bruce +45 3444 2613 [email protected] | Frederik Taylor Pitter +1 609 613 0568 [email protected] |
| Novo Nordisk A/S Investor Relations |
|---|
| Company |
| announcement No 25 / 2025 |
Field: Page; Sequence: 4
Field: /Page
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: August 19, 2025 NOVO NORDISK A/S Maziar Mike Doustdar Chief Executive Officer
Field: Rule-Page
Field: /Rule-Page
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.